Business, energy, technology, markets and global industry news from Business News Today

Gates Foundation

PharmaDeviceNews Gates Foundation
Merck is preparing a global access network for alimatravir as the investigational once-monthly oral HIV PrEP candidate advances through Phase 3 trials, with efficacy, affordability and manufacturing readiness set to determine its future public health impact. Representative image.
Pharma & Biotech

Merck is licensing alimatravir before Phase 3 ends. Can a monthly HIV pill beat the access clock?

Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.

Read More
A vaccine researcher reviews lung imaging and an investigational vial as Replicate Bioscience advances a self-replicating RNA tuberculosis vaccine with Gates Foundation funding. Representative image.
Pharma & Biotech

Replicate Bioscience wins Gates Foundation support for an ambitious TB vaccine strategy

Replicate Bioscience is extending its low-dose self-replicating RNA platform into tuberculosis, but immunological complexity, late-stage competition and global affordability create a demanding development path.

Read More
Representative image: Kanvas Biosciences’ Gates Foundation-backed microbiome therapy program highlights how synthetic live biotherapeutics could target maternal environmental enteric dysfunction, a gut disorder linked to undernutrition, low birthweight and newborn health risks in Southern Asia and Sub-Saharan Africa.
Pharma & Biotech

Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?

Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.

Read More
AptarGroup’s UDS powder nasal system selected for INNA-051 Phase II respiratory prophylaxis trial
Medical Devices & Diagnostics

AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray

Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.

Read More
Pharma & Biotech

Can philanthropic capital succeed where pharma failed in Gram-negative antibiotic discovery?

Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.

Read More